Clinical Data — Bear Stearns Healthcare Conference 2007
24 slides from Clinical Data's conference presentation, Sep 11, 2007

Slide 1: Bear Stearns Healthcare Conference September 11, 2007
Bear Stearns Healthcare Conference September 11, 2007

Slide 2: Forward-Looking Statements
Forward-Looking Statements SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This presentation contains certain forward-looking information about Clinical Data and its subsidiaries that is intended to be covered by the safe harbor for "forward-looking statements" provi

Slide 3: Corporate Snapshot
Corporate Snapshot Ticker CLDA 52 Week Price Range $13.50 to $29.68* Current Price $29.07* Market Cap $397.07 Million* Corporate Focus 1. Propriety Pharmacogenetic Tests 2. Targeted Therapeutics 3. Pharmacogenomics and Molecular Services for Clinical Trials and Research Capital Focus Vilazodone Clin

Slide 4: Clinical Data Mission
Clinical Data Mission Clinical Data is dedicated to bringing the value of pharmacogenetic testing and targeted therapeutics into mainstream clinical care to benefit providers, payers and patients

Slide 5: Clinical Data - Compelling Business
Clinical Data - Compelling Business Propriety pharmacogenetic tests and therapeutics High margins, large markets, low development costs Existing revenue base Strong value proposition for providers, patients and payers Timely: regulatory and industry acknowledgement Leading expertise and know-how Fou

Slide 6: PGxPredict Tests - We Are Delivering
PGxPredict(tm) Tests - We Are Delivering (1) Prevalence & incidence rates exclude International markets. Sources: Selected industry and academic publications and resources. Test Long Q/T Cardiology ~100,000 (U.S.) 1/3,000 Clozapine-Induced Agranulocytosis Disease Incidence/ Prevalence Disease/Therap

Slide 7: Familion Gross Sales
Familion(r) Gross Sales Note: Sales figures are prior to implementation of field sales force

Slide 8: PGxPredict Tests - Pipeline
Cardiovascular CNS Oncology Inflammatory Diseases Pain PGxPredict Tests - Pipeline

Slide 9: Key Achievements
Key Achievements Company transformation Successful completion of Vilazodone Phase III pivotal trial without partnering Pharmacogenetic test launches in Fiscal Year 2007: PGxPredict: Warfarin PGxPredict: Clozapine PGxPredict: Rituximab Test pipeline candidates identified and in development Familion L

Slide 10: Vilazodone Phase III Study Preliminary Results
Vilazodone Phase III Study Preliminary Results

Slide 11: Vilazodone Opportunity
Vilazodone Opportunity Profile: Genetically guided dual serotonergic antidepressant Both SSRI and 5HT1A partial agonist Worldwide exclusive license to Vilazodone patent estate from Merck KGaA Biomarker intellectual property may extend patent life Antidepressant Market: 17 million Americans take anti

Slide 12: A Pivotal Study for Vilazodone
A Pivotal Study for Vilazodone A Randomized, Double-Blind, Placebo- Controlled Study Assessing the Efficacy and Safety of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder

Slide 13: Vilazodone Pivotal Study Design
Vilazodone Pivotal Study Design 8 week, single dose trial in major depressive disorder (MDD) Randomized, double-blind placebo controlled with >90% power for primary endpoint 10 US sites Dose titrated to 40 mg over 2 weeks IRB approved and conducted according to GCP standards

Slide 14: Vilazodone Pivotal Study Design
Vilazodone Pivotal Study Design Patients 18-65 years of age with a diagnosis of MDD according to DSM-IV-TR criteria Disease severity assessed by Score on HAM-D17 HAM-D item 1 (depressed mood) score ^ 2 Minimum baseline score of ^ 22 on HAMD17 required for enrollment Week 0 10 mg Week 1 20 mg Week 2

Slide 15: Study Met Primary Endpoint With a Highly Significant P-value
Study Met Primary Endpoint With a Highly Significant P-value Vilazodone Placebo P-value N 198 199 LS-Mean Change -12.9 -9.6 0.001 Change from Baseline in MADRS Total Score ITT, LOCF analysis

Slide 16: Trend Over Time Is Positive
Trend Over Time Is Positive Treatment p-value = 0.0004 Treatment-by-time Interaction p-value = 0.0002 ITT, Observed Cases analysis Placebo Vilazodone

Slide 17: Secondary Efficacy Endpoint Also Significant
Secondary Efficacy Endpoint Also Significant Vilazodone Placebo P-value n 198 199 LS-Mean Change -10.4 -8.6 0.022 Change from Baseline in HAMD17 Total Score *ITT, LOCF analysis

Slide 18: Overall Study Discontinuations Balanced Between Vilazodone and Placebo
Overall Study Discontinuations Balanced Between Vilazodone and Placebo Vilazodone N=205 Placebo N=205 Discontinued from the Study 53 (25.9%) 51 (24.9%) Reason for Discontinuation Lost to Follow-up 20 (37.7%) 18 (35.3%) Adverse Event 19 (35.8%) 10 (19.6%) Withdrawal of Consent 5 (9.4%) 12 (23.5%) Lac

Slide 19: Most Commonly Observed Adverse Events in Phase III Vilazodone Study
Treatment-emergent AEs with an incidence of ~5% or greater and ~twice or more the incidence in placebo patients Diarrhea Nausea Somnolence Continue to analyze in the context of the safety database for this compound Most Commonly Observed Adverse Events in Phase III Vilazodone Study Classified accord

Slide 20: Vilazodone Response Biomarkers Identified
Vilazodone Response Biomarkers Identified Both candidate genes and whole genome scans utilized Performed at our Cogenics laboratories Key genes in the serotonin pathway identify a large subset of the depressed population with higher than average response Analysis continues Patent filings underway

Slide 21: Conclusions
Conclusions Efficacy of Vilazodone versus placebo established in a pivotal trial with statistical significance of primary and supportive efficacy analyses MADRS as a sensitive indicator of drug effect with a highly significant p-value HAM-D as a secondary endpoint significant Trend over time also po

Slide 22: Vilazodone Development Milestones
Vilazodone Development Milestones Meet with FDA to discuss data and next steps in Vilazodone clinical trial program Conduct long-term safety study Manufacture of registration and commercial drug supply Target NDA filing in 2009 Potential to develop companion diagnostic test for Vilazodone with marke

Slide 23: Fiscal Year 2008 Objectives
Fiscal Year 2008 Objectives Advance Vilazodone development program with eye to NDA filing in 2009 Drive adoption of proprietary pharmacogenetic tests Sales force hired and launched August 2007 Acquire and develop proprietary genetic markers Commercialize new proprietary tests Enhance lab operations

Slide 24: Thank You
Thank You www.clda.com Investor inquiries: Stephanie Carrington 646-536-7017
Source: SEC EDGAR · 8-K filed Sep 11, 2007
More decks from Clinical Data Inc
J. P. Morgan Healthcare Conference 201127 slides · Jan 12, 2011
Technical Presentation (May 2010)10 slides · May 25, 2010
Rodman & Renshaw Global Investment Conference 200924 slides · Sep 9, 2009
BMO Capital Markets Focus on Healthcare Conference 200930 slides · Aug 5, 2009
Fifth Annual Noble Financial Equity Conference 200923 slides · Jun 9, 2009
Investor Presentation (January 2009)25 slides · Jan 12, 2009